title: The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.
authors.affiliation: Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: Storti
authors.affiliation: Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, Italy.
authors.forename: Denise
authors.initials: D
authors.lastname: Toscani
authors.affiliation: Laboratorio di Oncologia, Istituto Giannina Gaslini, Genova, Italy.
authors.forename: Irma
authors.initials: I
authors.lastname: Airoldi
authors.affiliation: Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Marchica
authors.affiliation: INSERM, U892, University of Nantes, CNRS, UMR 6299, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Maiga
authors.affiliation: Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, Italy.
authors.forename: Marina
authors.initials: M
authors.lastname: Bolzoni
authors.affiliation: Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Fiorini
authors.affiliation: Pathologic Anatomy and Histology, "Azienda Ospedaliero-Universitaria" of Parma, Italy.
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Campanini
authors.affiliation: Pathologic Anatomy and Histology, "Azienda Ospedaliero-Universitaria" of Parma, Italy.
authors.forename: Eugenia
authors.initials: E
authors.lastname: Martella
authors.affiliation: Pathologic Anatomy and Histology, "Azienda Ospedaliero-Universitaria" of Parma, Italy.
authors.forename: Cristina
authors.initials: C
authors.lastname: Mancini
authors.affiliation: Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Guasco
authors.affiliation: Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, Italy Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Ferri
authors.affiliation: Department of Medical-Veterinary Science, University of Parma, Italy.
authors.forename: Gaetano
authors.initials: G
authors.lastname: Donofrio
authors.affiliation: Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, Italy.
authors.forename: Franco
authors.initials: F
authors.lastname: Aversa
authors.affiliation: INSERM, U892, University of Nantes, CNRS, UMR 6299, France.
authors.forename: Martine
authors.initials: M
authors.lastname: Amiot
authors.affiliation: Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, Italy nicola.giuliani@unipr.it.
authors.forename: Nicola
authors.initials: N
authors.lastname: Giuliani
mesh_terms: D000818:Animals; D053148:Caspase 3 / Q000235:genetics / Q000276:immunology; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000235:genetics / Q000276:immunology; D004195:Disease Models, Animal; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000276:immunology; D051740:Ikaros Transcription Factor / Q000235:genetics / Q000276:immunology; D007155:Immunologic Factors / Q000494:pharmacology*; D050835:Interferon Regulatory Factors / Q000235:genetics / Q000276:immunology; D000077269:Lenalidomide; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D019950:Mitogen-Activated Protein Kinase 1 / Q000235:genetics / Q000276:immunology; D048052:Mitogen-Activated Protein Kinase 3 / Q000235:genetics / Q000276:immunology; D009101:Multiple Myeloma / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D010950:Plasma Cells / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism; D044786:S-Phase Kinase-Associated Proteins / Q000235:genetics / Q000276:immunology; D015398:Signal Transduction; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000494:pharmacology; D015534:Trans-Activators / Q000235:genetics / Q000276:immunology; D000099218:Interferon Regulatory Factor-4
chemical_list: D053148:Caspase 3; D050760:Cyclin-Dependent Kinase Inhibitor p27; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D051740:Ikaros Transcription Factor; D007155:Immunologic Factors; D050835:Interferon Regulatory Factors; D000077269:Lenalidomide; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D034741:RNA, Small Interfering; D044786:S-Phase Kinase-Associated Proteins; D013792:Thalidomide; D015534:Trans-Activators; D000099218:Interferon Regulatory Factor-4; C497443:Hif1a protein, mouse; C491396:Ikzf3 protein, mouse; C497238:Zfpn1a1 protein, mouse; C535148:Mapk1 protein, mouse; C505409:Casp3 protein, mouse
keywords: hypoxia inducible factor (HIF)-1α suppression; in vivo; lenalidomide sensitivity; multiple myeloma